Sutro Biopharma, Inc. (STRO) Presents at AACR Annual Meeting 2026 - Slideshow

Sutro Biopharma presented at the 2026 AACR Annual Meeting, showcasing its latest advancements in precision oncology and antibody-drug conjugate (ADC) development. The company’s slideshow highlighted clinical progress in its lead programs, including updated data on STRO-002 for ovarian cancer and STRO-001 for multiple myeloma. Key focus areas included next-generation ADC platforms leveraging cell-free protein synthesis, a proprietary technology enabling rapid, scalable production of complex biologics. Preclinical and early-stage clinical results demonstrated improved tumor targeting and reduced toxicity, positioning Sutro as a leader in engineered therapeutics. Investor and scientific interest centered on the potential of Sutro’s pipeline to address unmet needs in hard-to-treat cancers through innovative quantum-inspired computational design.